Table 1.
Demographic and baseline disease characteristics of study population
| Characteristic (n = 1700 unless stated otherwise) | n (%)/* median (IQR) |
|---|---|
| Age (n = 1699), years | 33.0 (24.5–43.7)* |
| Gender | |
| Female | 1506 (88.6) |
| Male | 194 (11.4) |
| Enrolment location | |
| Canada | 397 (23.4) |
| USA | 463 (27.2) |
| Mexico | 210 (12.4) |
| Europe | 470 (27.7) |
| Asia | 160 (9.4) |
| Race/ethnicity | |
| Caucasian | 843 (49.6) |
| Hispanic | 262 (15.4) |
| Asian | 254 (14.9) |
| African origin | 278 (16.4) |
| Other | 63 (3.7) |
| Disease activity/phenotype | |
| SLEDAI-2K (n = 1693) | 4 (2–8)* |
| SLICC/ACR-Damage Index ≥1 | 391 (23.0) |
| Active renal diseasea | 436 (25.7) |
| Anti-dsDNA positive (n = 1541) | 613 (39.8) |
| Low complement (n = 1548)b | 582 (37.6) |
| Medication use | |
| Oral GC use prior to enrolment (n = 1699) | 1189 (70.0) |
| Average GC dosec (n = 1179), mg/day | 20.0 (10.0–30.0)* |
| Highest GC dosec (n = 1183), mg/day | 40.0 (20.0–60.0)* |
| Immunosuppressant use | 684 (40.2) |
| Antimalarial use | 1152 (67.8) |
| Co-morbidities | |
| Hypertension (n = 1683) | 758 (45.0) |
| Diabetes mellitus (n = 1682) | 61 (3.6) |
| Current smoker (n = 1698) | 252 (14.8) |
| Post-menopausal (n = 1506)d | 213 (14.1) |
| BMI, mean (s.d.) (n = 1672), kg/m2 | 25.7 (5.9) |
*Values are in median (IQR).
a
Active nephritis or any renal item on SLEDAI-2K (haematuria, proteinuria, pyuria or casts).
b
Decrease in CH50, C3 or C4 below the lower limit of normal for testing laboratory.
c
Average/highest GC doses of zero excluded from calculation.
d
Percentage of women. IQR, interquartile range.